News | 16 May 2021
Aarti Drugs Q4FY21 consolidated net profit drops to Rs. 51.65 Cr
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Financial support is being provided as a grant from the Government of India
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The company is working closely with its six manufacturing partners in India
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Subscribe To Our Newsletter & Stay Updated
